Abstract
To check the effect of zoledronate in bone remodeling during bone healing. Thirty rabbits were divided into two groups of fifteen animals each (control and experimental group respectively). Shaft osteotomy was performed on the cranial portion of the fibula of each animal. In the experimental group, a single dose of 0.04mg/kg of zoledronate was administered. In the control group, the same volume of bi-distilled water was administered. After one, two and four weeks, animals of both groups were killed and histological sections of the fibular metaphyseal area were examined histomorphometrically. The parameters analyzed were tissue volume (TV), fractional trabecular bone volume (BV/TV) and fractional medullary fibrous volume (FbV/TV). Tissue volume increased in the experimental group (237.2mm(2).10-2) compared to the control (166.62mm(2).10-2). Trabecular bone volume was significantly larger in the experimental (60.2%) than in the control group (34.8%). The amount of fibrosis volume decreased in the experimental group (22%) compared to the control (49.4%). The effect of zoledronate is characterized by accentuated stimulus of bone formation in the metaphyseal area, resulting in a larger amount of trabecular bone volume and little fibrosis volume.
Highlights
Experimental designBisphosphonates are used in the clinical treatment of several diseases that run their course along with pathological fractures and alteration of bone remodeling, such as osteoporosis, bone metastases, malignant hypercalcemia, Paget’s disease, hyperparathyroidism and osteogenesis imperfecta[1,2,3]
Trabecular bone volume was significantly larger in the experimental (60.2%) than in the control group (34.8%).The amount of fibrosis volume decreased in the experimental group (22%) compared to the control (49.4%)
The effect of zoledronate is characterized by accentuated stimulus of bone formation in the metaphyseal area, resulting in a larger amount of trabecular bone volume and little fibrosis volume
Summary
Experimental designBisphosphonates are used in the clinical treatment of several diseases that run their course along with pathological fractures and alteration of bone remodeling, such as osteoporosis, bone metastases, malignant hypercalcemia, Paget’s disease, hyperparathyroidism and osteogenesis imperfecta[1,2,3]. It is believed that bisphosphonates do not modify the reparative pattern of the callus , 6,7,8 but there are not consistents reports about the effects of these drugs on bone remodeling (formation and resorption) process during fracture healing. It has been observed decrease in bone mineral density of the tibial (44%) and femoral (61%) metaphysis after osteotomy for limb lengthening[9]. Stress-shielding or immobilizatiom create osteopenic bone adjacent to the lesion (fracture) site that is more susceptible to refracture This loss was only partially recovered at two years after osteotomy[6,9]. The purpose of this study is to check the effect of zoledronate, the most powerful bisphophonate in clinical use, in the histology of the metaphyseal trabecular bone, by means of a controlled experimental model in rabbit, submitted to fibular osteotomy in accordance with the method described by Matos in 200110
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
